drugset / Trial / NCT00254163
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to find out what effects (good and bad) the combination of Nipent+Cytoxan+Rituxan has on CLL cancer compared to Fludara+Cytoxan+Rituxan. While all of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of other cancers, these combinations are experimental for the treatment of CLL.
Timeline
- Start
- 2003-12
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fludarabine | Small molecule | — | — |
| Subject | Pentostatin | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |